Equity Brief: Stocks batten down the hatches
Ken Odeluga July 30, 2019 1:53 AM
It’s a session of sharp contrasts for major markets as Dow Industrials eke out a moderate gain, whilst tech stocks weigh the Nasdaq down again and Britain’s FTSE 100 shines
Stock market snapshot as of [29/7/2019 6:22 PM]
- It’s a session of sharp contrasts for major markets as Dow Industrials eke out a moderate gain, whilst tech stocks weigh the Nasdaq down again and Britain’s FTSE 100 outshines European counterparts with its best one-day rise since June
- Global exporters based in the UK powered the country’s benchmark 3% higher at one point as the drum beat harder for a no-deal Brexit, sending sterling to fresh two-plus year lows
- Elsewhere, more trade sabre rattling accounts for a less than sure-footed start to a busy week of earnings, central bank meetings and other top-tier economic events
- Ironically, Apple is a tech-sector exception as its stock rises 1%. It is spared the day’s turbulence as Wall Street appears to anticipate third-quarter results that could pace modest expectations when they’re released on Tuesday. That’s despite U.S. President Trump declining, with much fanfare to give, the iPhone maker a ‘waiver’ in the event of tariffs being imposed on some of the goods it has made in China
- Other tech giants fare worse as Amazon, Netflix and Facebook remain under pressure. Increasing regulatory cloud cover and mixed earnings over the last few days help account for investors’ retreat
- Anticipation of another key event—Wednesday’s Fed policy announcement, and likely cut—is almost certainly responsible for a fresh Treasury yield headwind. The 10-year rate was down for a second day to stand at 2.056% a short while ago from Friday’s 2.070% finish. That slide comes despite the dollar surging to the highest in almost two months, with a little help from sterling. Greenback revival vibes could well be sending a chill across Wall Street too
- Investors are likely to hold off from punchy positions as high-level U.S.-China talks resume on Tuesday. Treasury Secretary Steven Mnuchin and arch China hawk Robert Lighthizer, Trade Representative, will lead the Washington delegation. A hefty dose of scepticism is advisable ahead of the two days of discussions. Washington and Beijing positions look as intractable as they seemed in May when talks broke down in acrimony. At least the language on both sides sounds less incendiary, for the moment
- Health and retail shares are in demand in Europe and the U.S., though that appearance is mostly skewed by just a handful of stocks. Just Eat, the British take-away food platform zoomed almost 23% higher as analysts signalled that it could be ‘in play’. That follows news that the £4.3bn group is in talks to be acquired by Dutch rival Takeaway.com, worth just slightly more, in dollar terms
- AstraZeneca led Europe’s pharma sector and health stocks generally, adding 3%. Investors are optimistic about a lawsuit it launched last week against a generic competitor. Pfizer’s multibillion dollar mega deal with Mylan is also adding froth to the sector. Mylan was among the big U.S. large-cap movers, with a 14% jump. Roche offset some of the industry’s cheer with a slight fall after data showed weaker sales of some key medicines
- Perhaps just as remarkable is the 6% slip by Beyond Meat, the plant-based meat substitute maker whose shares are only up about 800% since their IPO in May. With earnings out tonight it might just be that most upside that could possibly be hitched to results is now baked well in to the price
Upcoming corporate highlights
BMO: before market open NTS: no time specified
Upcoming economic highlights
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
StoneX Financial Pte. Ltd. is not under any obligation to update this report.
Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.